Business
Aldeyra Therapeutics Announces Chief Financial Officer Transition
LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Chief Financial Officer (CFO) and Treasurer
About this update from Aldeyra Therapeutics, Inc.
[{"type":"text","content":" LEXINGTON, Mass.--(BUSINESS WIRE)--\nAldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Chief Financial Officer (CFO) and Treasurer Joshua Reed tendered his resignation to pursue other career opportunities. Mr. Reed will continue to serve as CFO and Treasurer until May 10, 2022 (the Resignation Date) to assist with the transition of his responsibilities and to participate in Aldeyra’s upcoming earnings conference call to discuss its financial results for the quarter ended March 31, 2022. Effective as of the Resignation Date, Aldeyra plans to appoint its current Vice President and Controller, Bruce Greenberg, CPA to serve as its Vice President of Finance, Interim CFO, and Treasurer.\n\n“During his tenure, Joshua has played an integral role in executing on our strategic financial and business objectives,” stated Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra. “He has overseen the completion of a number of capital markets transactions, expanded our banking relationships, and served as a strong business partner. I thank Joshua for his many contributions and wish him well in the next chapter of his career.\n\n“I also want to congratulate Bruce on his appointment as Interim CFO. Since joining Aldeyra at the end of 2019, Bruce has contributed significant expertise in the areas of financial analysis, budgeting, and forecasting,” Dr. Brady stated. “His extensive knowledge of Aldeyra, together with his significant industry and financial experience, are well suited to help us execute our strategic priorities.”\n\nMr. Reed stated, “I have enjoyed the opportunity to work with Todd, the Board of Directors, and our entire team. I am extremely proud of the clinical development and capital milestones we have achieved over the past three and a half years, and I look forward to monitoring Aldeyra’s progress as the Company continues to advance its ophthalmology and systemic disease programs toward commercialization.”\n\nMr. Greenberg, who joined Aldeyra as Vice President, Controller in 2019, has more than 25 years of accounting and financial operations experience. Prior to Aldeyra, from May 2017 to December 2019, he served as the Corporate Controller for Karyopharm Therapeutics Inc. (Nasdaq: KPTI), which develops and commercializes drugs for use in oncological treatments. Previously, he held posi...